MARKET

NSPR

NSPR

Inspiremd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.140
+0.100
+4.90%
Opening 10:47 05/27 EDT
OPEN
2.150
PREV CLOSE
2.040
HIGH
2.150
LOW
2.110
VOLUME
2.04K
TURNOVER
4.16K
52 WEEK HIGH
6.82
52 WEEK LOW
1.910
MARKET CAP
17.81M
P/E (TTM)
-1.0285
1D
5D
1M
3M
1Y
5Y
InspireMD Q1 EPS $(0.57) Beats $(0.80) Estimate, Sales $1.18M Miss $1.40M Estimate
InspireMD (AMEX:NSPR) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.80) by 28.75 percent. The company reported quarterly sales of $1.18 million which missed the analyst
Benzinga · 05/10 12:01
Recap: InspireMD Q1 Earnings
  InspireMD (NASDAQ:NSPR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 12:00
BRIEF-Inspiremd Reports First Quarter 2022 Financial Results And Business Update
reuters.com · 05/10 11:31
InspireMD Reports First Quarter 2022 Financial Results and Business Update
- 20% growth in CGuard™ revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard™ clinical advantages -...
GlobeNewswire · 05/10 11:30
InspireMD GAAP EPS of -$0.57, revenue of $1.18M
InspireMD press release (NASDAQ:NSPR): Q1 GAAP EPS of -$0.57. Revenue of $1.18M (+16.8% Y/Y). Cash and cash equivalents of $7.8M as at Mar.31.
Seekingalpha · 05/10 10:27
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
-- Earnings Flash (NSPR) INSPIREMD Reports Q1 Revenue $1.16M, vs. Street Est of $1.4M
MT Newswires · 05/10 07:40
Notable earnings before Tuesday's open
ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS,
Seekingalpha · 05/09 15:06
More
No Data
Learn about the latest financial forecast of NSPR. Analyze the recent business situations of Inspiremd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NSPR stock price target is 5.25 with a high estimate of 5.25 and a low estimate of 5.25.
High5.25
Average5.25
Low5.25
Current 2.140
EPS
Actual
Estimate
-0.69-0.52-0.34-0.17
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 23
Institutional Holdings: 169.62K
% Owned: 2.04%
Shares Outstanding: 8.32M
TypeInstitutionsShares
Increased
2
2.49K
New
3
3.06K
Decreased
2
604
Sold Out
5
36.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.30%
Healthcare Equipment & Supplies
+2.27%
Key Executives
Non-Executive Chairman/Independent Director
Paul Stuka
President/Chief Executive Officer/Director
Marvin Slosman
Chief Financial Officer/Chief Administrative Officer/Treasurer/Secretary/IR Contact Officer
Craig Shore
Independent Director
Kathryn Arnold
Independent Director
Michael Berman
Independent Director
Thomas Kester
Independent Director
Campbell Rogers
Independent Director
Gary Roubin
No Data
No Data
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Webull offers kinds of InspireMD Inc stock information, including NASDAQ:NSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NSPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NSPR stock methods without spending real money on the virtual paper trading platform.